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Abstract
A critical question facing the field of metabolomics is whether data obtained from different centres 
can be effectively compared and combined. An important aspect of this is the inter-laboratory 
precision (reproducibility) of the analytical protocols used. We analysed human samples in six 
laboratories using different instrumentation but a common protocol (the AbsoluteIDQ™ p180 Kit) 
for the measurement of 189 metabolites via liquid chromatography (LC) or flow-injection analysis 
(FIA) coupled to tandem mass spectrometry (MS/MS). In spiked quality control (QC) samples 
82% metabolite measurements had an inter-laboratory precision of <20%, while 83% of averaged 
individual laboratory measurements were accurate to within 20%. For 20 typical biological 
samples (serum and plasma from healthy individuals) the median inter-laboratory CV was 7.6%, 
with 85% of metabolites exhibiting a median inter-laboratory CV of <20%. Precision was largely 
independent of the type of sample (serum or plasma) or the anticoagulant used but was reduced in 
*Corresponding author. Hector C. Keun, h.keun@imperial.ac.uk. 
Conflict of Interest Disclosure
The authors declare no competing financial interest.
Europe PMC Funders Group
Author Manuscript
Anal Chem. Author manuscript; available in PMC 2019 January 03.
Published in final edited form as:
Anal Chem. 2017 January 03; 89(1): 656–665. doi:10.1021/acs.analchem.6b02930.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
a sample from a patient with dyslipidaemia. The median inter-laboratory accuracy and precision of 
the assay for standard reference plasma (NIST SRM 1950) were 107% and 6.7%, respectively. 
Likely sources of irreproducibility were the near-LOD typical abundance of some metabolites and 
the degree of manual review and optimisation of peak integration in the LC-MS/MS data post-
acquisition. Normalisation to a reference material was crucial for the semi-quantitative FIA 
measurements. This is the first inter-laboratory assessment of a widely-used, targeted 
metabolomics assay illustrating the reproducibility of the protocol and how data generated on 
different instruments could be directly integrated in large-scale epidemiological studies.
Introduction
Metabolic profiling (often referred to as metabonomics or metabolomics)1,2 of body fluids 
provides a unique view of the metabolic status of an individual and their exposure to dietary 
or environmental factors, and can inform as to how these interact with genotype or are 
modulated by drugs. Liquid chromatography mass spectrometry (LC-MS) based platforms 
are most widely used for metabolomics studies and often exhibit greater sensitivity and 
metabolite coverage compared to other techniques. Many studies use high-mass resolution 
detectors, such as quadrupole time-of-flight (Q-ToF) and Orbitrap instruments, to screen 
biomolecules in an untargeted manner. Alternatively targeted approaches, that preselect 
species to measure, typically use multiple reaction monitoring (MRM) on tandem MS 
(MS/MS) low-mass resolution detectors to enhance sensitivity and selectivity.
The Biocrates AbsoluteIDQ™ p180 kit is a commercially available targeted metabolomics 
assay that can be used on a variety of LC-MS/MS triple quadrupole instruments. The kit has 
already been applied to many studies of human serum and plasma, including clinical studies 
for disease biomarker discovery,3–5 biomarker of target engagement6 and several large-
scale prospective cohort studies (with number of participants n>1000) such as EPIC 
(European Prospective Investigation into Cancer and Nutrition)3,7–10 and KORA 
(Cooperative Health Research in the Region of Augsburg).5,11,12 Data are now available 
regarding many critical aspects of the use of this platform, including the influence of pre-
analytical factors,13,14 the differences between human plasma and serum metabolite 
profiles,15 the evaluation of between- and within- person metabolite variation7,16 and the 
influence of common confounders such as age,17 anthropometry,18 smoking,19 the effect of 
sleep restriction and circadian clock disruption20 as well as assessment of heredity21 and 
genome-wide perspectives of variation in human metabolism.11
Despite the rapid progress in the use of metabolomics platforms a key limitation is currently 
the lack of methodological standardisation and testing of the comparability of data between 
laboratories. Very few multicentre metabolomics studies of reproducibility have been 
reported to date and those that exist have primarily used untargeted methods, and so have 
been unable to define metabolite specific data on reproducibility or accuracy. Both high 
intra-laboratory precision (across many samples over an extended period of time) and inter-
laboratory precision (across different centres, instruments and studies) are critical for 
pooling of data and conducting meta-analyses on clinical and molecular epidemiological 
studies. In a conventional evaluation of precision and accuracy, the background matrix is 
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rarely varied. It is also very difficult, for blood metabolomics studies, to obtain a 
representative analyte-free matrix. This is inadequate when we are often trying to interpret 
modest concentration differences in a few metabolites in the context of large changes in the 
background composition, e.g. in plasma the lipoprotein and protein composition can vary 
dramatically affecting the sample matrix greatly. Therefore, we sought to evaluate the inter-
laboratory reproducibility of this targeted metabolomics assay in the context of a panel of 
different test human plasma and serum samples, and also compared the effects of different 
anticoagulants on reproducibility. Across six participating laboratories several different 
instrumental platforms were used, allowing assessment of the comparability of data derived 
from different platforms. Finally, we assessed the pros and cons of data normalisation to 
improve the comparability of data generated in different laboratories. Our current work 
represents the first inter-laboratory assessment of the reproducibility of the widely-used, 
targeted LC-MS metabolomics AbsoluteIDQ™ p180 kit on human plasma and serum, and 
provides critical knowledge for the successful integration and validation of large-scale 
metabolomics biomarker datasets generated from different laboratories, on epidemiological 
and drug development research.
Material and Methods
Twenty-six test materials, including spiked quality control (QC) samples with known 
concentrations of metabolites, the NIST (National Institute of Standards and Technology) 
reference human plasma (SRM 1950) and serum/plasma collected from volunteers were 
distributed to six laboratories and independently analysed using the AbsoluteIDQ™ p180 kit 
following the manufacturer’s protocol but using different combinations of MS instrument 
and HPLC/UHPLC. The kit allows the targeted analysis of up to 189 metabolites (see Table 
S-5) in the metabolite classes of amino acids, biogenic amines, acylcarnitines, 
glycerophospholipids, sphingolipids and sum of hexoses, covering a wide range of analytes 
and metabolic pathways in one targeted assay. The Kit consists of a single sample 
processing procedure, although two separate MS analytical runs, a combination of liquid 
chromatography (LC) and flow-injection analysis (FIA) coupled to tandem mass 
spectrometry (MS/MS). Isotope-labelled and chemically homologous internal standards are 
used for quantification, and in total 56 analytes are fully validated as absolutely quantitative.
Of the total 189 metabolites measured, 43 metabolites are measured by LC-MS/MS and 146 
metabolites by FIA-MS/MS. The amino acids (21) and biogenic amines (22) are analysed 
quantitatively by LC-ESI-MS/MS, with the use of external calibration standards in seven 
different concentrations and isotope labelled internal standards for most analytes. All amino 
acids and amines are fully validated as absolutely quantitative. The acylcarnitines (40), 
glycerophospholipids (90), sphingolipids (15) and sum of hexoses (1) are analysed by FIA-
ESI-MS/MS, using a one point internal standard calibration with representative internal 
standards (9 isotope-labelled acylcarnitines, 1 isotope-labelled hexose, 1 non-labelled lyso-
PC, 2 non-labelled PCs, 1 non-labelled SM, a total of 14 internal standards). In terms of 
quantification, the lipids and a subset of acylcarnitines are called “semi-quantitative” since 
specific standards were not commercially available and a verification of the accuracy was 
not possible by the manufacturer. 12 acylcarnitines and the sum of hexoses are fully 
validated as absolutely quantitative. In addition many of the FIA-detected, semi-quantitative 
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lipid concentrations represent total concentrations of possible isobars and structural isomers. 
The results for the metabolites are displayed with a corresponding short name with the total 
length of side chains and the total number of double bonds. The kit utilises a patented 96-
well plate design which allows simultaneous efficient sample derivatisation and reproducible 
analyte extraction. The kit is suitable for manual or automated high throughput operation, 
and it requires only a very small sample volume of 10 µL and comes with human plasma 
based quality controls in 3 concentration levels (low, medium, high) which can be used for 
quality control purposes but also potentially for batch normalisation. The baseline analytical 
validation and performance of the kit has been described by the manufacturer22 and a 
summary is given in Tables S-14 and S-16. Moreover three of the participating laboratories 
provided further data on the inter-plate and intra-plate variability (Tables, S-11, S-12 and 
S-13).
Study population/test materials
A total of 26 test materials were used, replicated 3-6 times, utilising a total of 85 positions 
on a single kit 96-well plate, in each participating laboratory (Table S-1):
• 3 QCs provided by the manufacturer with three concentration levels of 59 
standards spiked into a plasma background: p180-MetaDis QC levels 1-3; low 
(x5 replicates per plate), medium (x5 replicates per plate), and high (x3 
replicates per plate). Total 13 positions per plate.
• 1 NIST standard reference material (SRM 1950, lithium heparin plasma) (x3 
replicates per plate).
• 1 EDTA plasma sample from an individual with dyslipidaemia (x3 replicates per 
plate).
• 20 test materials (x3 replicates each per plate) collected from 8 healthy 
individuals. For 4 individuals EDTA plasma only was collected (Test samples 02 
to 05). For the other 4 individuals repeated collections with three different 
anticoagulants (EDTA, citrate and heparin) and serum were conducted Test 
Samples 07-1 to 10-4).
• 1 pooled QC Sample (QCP), prepared by each individual laboratory by pooling 
10 µL of each of 16 test materials (4 individuals x 4 collections, Test Samples 
07-1 to 10-4) (x6 replicates per plate).
All samples were collated, recoded, aliquoted and distributed by laboratory E to the other 
laboratories with those participants blinded to the specific identify of each test material until 
data acquisition was completed. All experimental procedures were approved by the local 
Ethics Committee.
Metabolomics measurements
Basic common guidance (Protocol S-1) was agreed on the cleaning and benchmarking of 
instruments prior to analysis, and also the run order and the position of samples in 96 well 
plates, with vertical pipetting and run order mode (Figure S-1). Plasma and serum metabolite 
concentrations were determined using the targeted metabolomics kit AbsoluteIDQ™ p180 
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kit (BIOCRATES Life Sciences AG, Innsbruck, Austria). The samples were prepared, by all 
participating laboratories, according to the manufactures’s protocol22 (details in Protocol 
S-2).
Laboratory instrumentation – MS analysis
Each laboratory followed the manufacturer’s protocol but used different UHPLC/HPLC or 
MS/MS platforms (details in Protocol S-2). Laboratories A, B, C and E used HPLC with 
SCIEX mass spectrometers. Lab F used Waters UHPLC with a Waters mass spectrometer. 
Lab D used a combination of Waters UHPLC with a SCIEX mass spectrometer. Two 
examples of typical MS analytical procedures are described in Protocol S-2.
Data transformation - Statistical analysis
For the LC-MS/MS assay, the metabolites were quantified by stable isotope dilution and 
seven point calibration curves. For the FIA-MS/MS assay, metabolite concentrations were 
calculated using a one point internal standard calibration, and are also isotope corrected. 
Metabolites were quantified (results shown in µM concentration units) according to the 
manufacturer’s protocol using the MetIDQ™ Boron software for targeted metabolomic data 
processing and management. Blank PBS (phosphate-buffered saline) samples (3 replicates) 
were used for the calculation of the limits of detection (LOD). The median values of all PBS 
samples on the plate were calculated as approximation of the background noise per 
metabolite, and 3 times this value was calculated by each laboratory as the LOD (Table S-15 
includes the LODs for all the metabolites as calculated by each laboratory). Raw data from 
each participating laboratory were exported as .xls format and then collated by lab B for 
further statistical analysis and inter-laboratory comparison. For each test sample, 
concentration means, accuracies and intra-lab CVs were calculated for the metabolites 
having at least two valid replicates (Table S-17). For each test sample, an inter-lab CV was 
then calculated for the metabolites that had valid intra-lab CV from at least three 
laboratories. Data are available on request and will also become publicly available.
Missing data, exclusions and outliers
In total, across all laboratories 91,025 individual metabolite measurements out of a 
theoretical total of 96,390 (189 metabolites x 85 samples x 6 laboratories) (94.4 %), were 
included in our study. Principal reasons for missing data and exclusions were: the 
manufacturer’s protocol indicated not to acquire data for some metabolites for specific 
instrumental platforms due to known selectivity issues (‘not acquired’ or ‘NQ’, 850 
measurements 0.88%); no peak was detected or the peak could not fit to the calibration 
curve (‘N/A’ reported, 842 measurements 0.87%); or the integral value gave a negative or 
zero concentration according to the calibration curve (zero value reported, 2182 
measurements 2.26%). Laboratories that used HPLC did not acquire data for sarcosine, 
whereas laboratories that used UHPLC did not acquire data for total-DMA. Laboratories that 
used Waters mass spectrometry instruments did not acquire data for four lipids (PC aa 
C30:2, PC aa C32:2, PC aa C38:1, SM C22:3). Other exclusions included two cases of 
human error, specifically the omission of the addition of internal standards for four samples 
for Lab F and an error in the preparation of the six QCP samples for lab D. Very few 
measurements (0.4%) were considered to be unexplained outliers, as assessed by Principal 
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Components Analysis (PCA; Figure S-2 just 2 samples of 510) or by visual inspection (1 
measurement). To avoid imputation during subsequent statistical analysis recorded values 
below the limits of detection (BLD) were not excluded from the analysis. Table S-2 gives a 
detailed breakdown of why certain data were missing or excluded.
Results
Assay performance: Accuracy, intra- and inter-laboratory reproducibility of spiked QC 
samples
In our analyses we first considered the reproducibility of the quality control (QC) samples 
supplied routinely by the manufacturer. These consist of mixtures of human plasma spiked 
with 59 metabolites (42 and 17 measured by LC and FIA respectively) to 3 nominal 
concentrations (‘low’ – QC1, ‘medium’ – QC2, ‘high’ – QC3) allowing assessment of intra- 
and inter-laboratory accuracy and precision for these metabolites (Table S-3). Two of the 
concentrations values were not provided (PEA and sarcosine for ‘low’ – QC1), and therefore 
data for these are not presented. Data for sarcosine for laboratories A, B, C and E were not 
acquired. Only one laboratory (D) reported further missing data (for histamine, putrescine 
and PEA).
Overall, 144 (82%) of the 175 repeated metabolite measurements (59 metabolites x 3 
concentration levels – 2 missing), had an inter-laboratory precision of <20%. For the 
majority of the metabolites assessed (41/59), the reproducibility was <20% at all three 
concentrations, and for 18 metabolites (16 and 2 measured by LC and FIA respectively) the 
reproducibility was >20% for at least one concentration level. In terms of precision at the 
level of individual laboratories, of the 1042 repeated measurements (59 metabolites x 3 
concentrations x 6 laboratories – 20 missing), 1008 (96.7%) had an intra-laboratory 
CV<20% and 771 (74%) had a CV<10% (for a full breakdown of QC sample data by 
laboratory see Table S-3). Moreover, 35/59 metabolites had intra-laboratory precision <20% 
for all three concentration levels and all six laboratories. For 48/59 metabolites the accuracy 
of the assay as determined by the averaged value across laboratories, was within 20% of the 
nominal concentration at all three concentrations, while 83% (863 of 1042) of averaged 
intra-laboratory measurements were within 20% of nominal concentration (Table S-3). It 
was observed that 7/59 metabolites had all accuracies within 20% for all three concentration 
levels and all six laboratories; at threshold of 30% this reached 32/59 metabolites.
Of the 18 metabolites exceeding an inter-laboratory precision of 20% for at least one 
concentration level, 10 metabolites did so for only one concentration level. 6 metabolites 
(glutamate, acetylornithine and methioninesulfoxide, cis-4-hydroxyproline (c4-OH-Pro), 
DOPA and dopamine) did so for the lowest concentration, while 1 metabolite (PEA) did so 
for the medium level, and 3 (kynurenine, lysine, ornithine) for the highest concentration 
only. Of the remaining 8 metabolites (sphingomyelin C18:0, dodecanoylcarnitine (C12), 
symmetric-dimethylarginine (SDMA), spermine, spermidine, trans-4-hydroxyproline (t-4-
OH-Pro), carnosine and nitro-Tyr), with poor reproducibility for at least two concentration 
levels, dodecanoylcarnitine (C12) was measured at consistently higher concentrations 
(˜150%) for just Lab C and high accuracy and precision were observed for the other 
laboratories. Measurements of sphingomyelin C18:0 were precise but inaccurate by a fixed 
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percentage within Lab A (74%), Lab B (49%) and Lab F (185%), indicating that 
normalisation by a single multiplicative factor could improve inter-laboratory agreement for 
this and potentially other FIA-detected metabolites. For SDMA, only lab B reported 
acceptable analytical performance; one laboratory (F) reported values ˜10-fold higher than 
the nominal values while for four labs the accuracy ranged between 39.2% and 230%. For 
DOPA all laboratories reported poor accuracy results for the low concentration, whereas for 
dopamine two laboratories reported poor accuracy results again for the low concentration. 
The poor reproducibility of the polyamines spermine, spermidine and carnosine were 
primarily the result of anomalously low quantities reported by laboratory D (<3% of 
nominal value) while for t-4-OH-Pro laboratory D reported anomalously high quantities (up 
to 454%) and also reported poor accuracy for nitro-Tyr (12-208%). Notably for 8 
metabolites (spermine, spermidine, t-4-OH-Pro, carnosine, nitro-Tyr, Glu, c-4-OH-Pro and 
PEA) an apparently low reproducibility could be attributed to the poor accuracy of a single 
outlying laboratory (see Table S-3). Excluding data from laboratory D for the analysis of 
these metabolites brought inter-laboratory precision to within 20% in each case.
Normalisation
We next analysed the reproducibility of the 20 test materials representing typical samples 
taken from healthy individuals (serum and plasma samples: Test Samples 02 to 05 and Test 
Samples 07-1 to 10-4) which formed our primary test set. Initial PCA indicated that 
systematic differences were present between the laboratories in the metabolic profiles 
(Figure S-3), particularly the FIA-detected lipid profile. Therefore, we investigated methods 
for normalising the data to correct for batch and/or instrumental platform effects.
In order to define a single normalisation factor for each metabolite per laboratory we used a 
single reference sample from each batch and calculated the fold change for each metabolite 
relative to the reference sample value for a specific reference laboratory. Thus, the 
normalised value Xij for a metabolite i, for a laboratory j was given by:
Normalised Xi j = Xi j *
mean value(metabolite i) in reference material from reference Lab
mean value(metabolite i) in reference material from Lab j
where, i= 1-189 are measured metabolites, and j=1-5 were the participating laboratories.
As all laboratories had some missing or zero values (Tables S-5 and S-6), the laboratory with 
the least overall missing data (Lab B) was selected as the reference laboratory. For the 
reference material we tested both TS 06 (NIST SRM 1950 plasma) and the spiked QC2 
(Biocrates p180-MetaDis QC level 2), and also we investigated normalising to the mean or 
median of each reference material. For both reference materials it appears that normalising 
to the mean was marginally more effective than normalising to the median. Figure 1 and 
Figure 2 (Table S-4) show the effect of normalisation on our primary test set. Normalisation 
using the NIST SRM 1950 produced a substantial improvement in the CV distribution: of a 
total of 3780 inter-laboratory CV values, the proportion of CV values <20% increased from 
54% to 84%. Normalisation using the QC2 samples also made improvements but to a lesser 
extent (72% of CVs <20%). For the metabolites quantified by LC-MS/MS the improvement 
in reproducibility of the data resulting from normalisation was only marginal (from 59% to 
Siskos et al. Page 7
Anal Chem. Author manuscript; available in PMC 2019 January 03.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
64% of CV<20% using the NIST SRM 1950), whereas for metabolites quantified via FIA-
MS/MS the inter-laboratory precision was greatly improved (from 53% to 90% of 
CV<20%). For sphingolipids in particular the effect was dramatic: of a total of 300 
sphingolipid inter-laboratory CVs calculated, 270 CVs were >30% before normalisation and 
272 CVs <20% post normalisation. In light of these findings normalisation was applied only 
to the FIA part of the assay for subsequent analysis, and the mean values of NIST SRM 
1950 used for adjustment. Unless explicitly stated, further analyses of our primary test set 
are presented using these ‘FIA only normalised’ data.
Inter-laboratory reproducibility (% CV) in 20 typical test materials
A full, per metabolite, breakdown of reproducibility is given in Table S-5, a per metabolite 
class in Table S-6, with summary values presented in Table 1 Across all 189 metabolites 
analysed with the AbsoluteIDQ™ p180 Kit, following normalisation of the FIA-quantified 
metabolites, the median inter-laboratory precision across 20 test materials was 7.6%. A high 
proportion (~85%) of the total measured metabolites (160 metabolites) had a median inter-
laboratory precision (<20%), with 123 metabolites exhibiting median inter-laboratory 
precision <10% (Figure 3). For 24 metabolites the median inter-laboratory precision across 
20 test materials was >20% and for a further 5 metabolites the calculation of inter-laboratory 
CV was not possible, due to missing data (with a minimum requirement of two replicates 
measurement for a given sample per lab, and for at least three laboratories per metabolite). 
The average ratio of intra-laboratory CV to inter-laboratory CV across all metabolites 
ranged from 1:1.4-1.5 for laboratories A, B, C & E while for laboratories D and F the ratio 
was ˜1:1, indicating that overall reproducibility was lower within these last two laboratories 
(Table S-7).
Breakdown of the reproducibility into metabolite classes revealed that with the exception of 
the ‘biogenic amines’, the median inter-laboratory precision for each class was also <20% 
(Table 1). FIA-normalisation made a dramatic improvement in the reproducibility of 
sphingolipids measurements (median CV from 68% to 6.7%) and also made a critical 
difference in the reproducibility of carnitines (median CV from 34% to 12%) which were 
frequently below the limits of detection (BLD) or missing (48%). For the remaining FIA 
part of the assay we observed a very high reproducibility (after normalisation) across the 
overwhelming majority of the metabolites across the 20 test materials: the median inter-
laboratory precision was 6.4 % for the di-acyl PCs (PC aa), 5.9 % for the alkyl-acyl PCs (PC 
ae), 8.1 % for the lyso PCs and 6.7 % for the sphingolipids. Laboratories that used Waters 
instruments did not acquire data for 4 of the lipids (PC aa C30:2, SM C22:3, PC aa C32:2, 
PC aa C38:1). Of these 4 lipids PC aa C30:2 and SM C22:3 also showed poor performance 
for some of the other laboratories and poor inter-laboratory precision. With the exceptions of 
aspartic acid (Asp) and glutamate (Glu) the precision of the amino acid analysis was very 
high (median 7.1%), with almost all of the concentration values being above the limits of 
detection.
Of the 45 metabolites reporting at least 30% of their data missing or BLD, 26 were 
carnitines indicating that the typical abundances of many of these metabolites in blood 
serum or plasma were below the operating limits of the assay (Table S-8). However, 
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mitigating this was the observation that after normalisation only 3 carnitines (C3:1, C5:1-
DC, C9) produced inter-laboratory CVs>20%. Of the 5 metabolites for which missing data 
precluded reproducibility analysis, sarcosine was not part of the assay for 4 laboratories due 
to the requirement of UHPLC for measurement. Between the two laboratories that did 
measure sarcosine the agreement was within ~10% (data not shown). For the other four 
metabolites (PEA, nitro-tyrosine, cis-4-OH-Pro and dopamine) all laboratories consistently 
reported extensive missing data (>80% in total) indicating that in normal serum/plasma these 
metabolites could not be detected reliably by the assay.
Of the 24 metabolites that produced a CV>20% (Table S-8), 12 also had a high proportion of 
missing values or BLD, although these were not always evenly distributed between 
laboratories (Table S-5). 11 of the 24 were of the ‘biogenic amine’ class and 13 were 
measured during the LC-MS step of the assay. For biogenic amines the average intra:inter-
laboratory CV ratio was also high (~1:3-6.9) compared to all other metabolites (Table S-7). 
For carnosine, DOPA and histamine the majority of values across laboratories were reported 
as missing or BLD indicating that in normal serum/plasma these metabolites were not 
detected reliably by the assay (Table S-5). Of the biogenic amines with highly variable 
detection across laboratories Ac-Orn was not detected by laboratory A and both laboratory 
D and F generated a high proportion of missing values (53% and 97%, respectively). 
Methionine sulphoxide (Met-SO) was not detected in 90% of samples by Laboratory D 
while laboratories E & F reported high numbers of missing values. Laboratory D also 
reported a high proportion of BLD values (95%) for alpha amino-adipic acid (Alpha-AAA). 
Laboratories B, D and F did not detect one or more of the polyamines putrescine, spermidine 
and spermine as reliably as other laboratories. SDMA was poorly detected by Laboratory A 
only (55% missing values) but reported with good precision in other laboratories. Of the 
amino acids with low reproducibility aspartic acid (Asp) was measured with an intra-
laboratory precision>20% for laboratories C and D. For the LC-MS detected metabolites 
only glutamic acid (Glu) and ADMA returned a high inter-laboratory CV despite typically 
good intra-laboratory precision and low numbers of missing samples. Overall this analysis 
indicated that the reliability and reproducibility of biogenic amine quantification in 
particular, was variable across laboratories as a result of both the relatively low abundance of 
several metabolites of this class in blood samples (compared to the LODs for the assay) and 
also differences in the level of individual operator review of the raw LC-MS data.
The effect of anti-coagulants, high lipids and manual sample pooling on inter-laboratory 
reproducibility
Table S-9 shows a comparison of inter-laboratory precision for sera and plasma samples 
obtained with different types of anti-coagulant from the same individuals. The overall 
reproducibility of serum data across all metabolites (median CV 6.9%) was marginally lower 
than for matched data across all laboratories generated on plasma (median CV 7.2-8.2%) 
with heparin plasma producing the highest values. This trend was observed for all metabolite 
classes detected by FIA but was less clear for LC-MS detected metabolites. Reproducibility 
measurements made on a sample from an individual with pathologically high blood lipids 
(Table S-9) revealed that inter-laboratory precision was substantially worse for 
phospholipids including sphingomyelins, with CVs increasing by ~4-fold (to 24-26%). 
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Increased CVs were also observed for hexoses and lyso-phosphatidylcholines (to 12.2 and 
13%, respectively). Metabolites detected by LC-MS appeared to be generally unaffected. We 
also considered the reproducibility of a pooled QC sample (QCP) generated from the 20 
typical biological test materials (Table S-9). Inter-laboratory precision for all classes of 
metabolites, with the exception of biogenic amines, was observed to be higher for the QCP 
than for the original test materials (data not shown). This suggests that the manual 
preparation of the pooled sample added discernible variability when comparing data from 
the assay between laboratories. This seemed to be the case with laboratory D which reported 
experimental issues and errors with the preparation of the QCP. With the exclusion of 
laboratory D, the median inter-laboratory precision for the QCP samples was comparable to 
the rest of the test material (Table S-9).
Inter-laboratory precision and accuracy of metabolite quantification compared to reference 
values for the NIST 1950 human plasma standard reference material
Reference values are currently available for 60 metabolic measurements on the NIST SRM 
1950 of which 19 overlap with the AbsoluteIDQ™ p180 Kit panel.23–25 Comparison of the 
estimated concentration of these metabolites from this assay to reference values revealed 
that the overall accuracy of the assay (the mean accuracy across laboratories) was within 
20% for 18/19 metabolites (Figure 4, Table S-10). The average accuracy of the assay across 
metabolites was 108% with accuracy>100% reported for 15/19 metabolites; this was 
consistent with a slight upward bias in the assay for most measurements. For the amino acid 
serine the bias was clearly present in all 6 laboratories (accuracy ranging from 133-155%). 
For laboratories D, E and F the upward bias was>20% in at least 4/19 metabolites. In terms 
of inter-laboratory reproducibility the assay performed very well, with CVs ranging from 
1.2% (alanine) to 12.1% (lysine).
Discussion
Very few studies have compared the inter-laboratory reproducibility of metabolomics data. 
Of those that have, the predominant focus has been on untargeted profiling methods. In an 
early study, a high reproducibility was reported for NMR spectroscopy analysis of urine in 
rodents, with >95% correlation and 4-8% inter-laboratory variability for measurements of 
three selected metabolites between two laboratories.26 Similarly high reproducibility was 
reported for NMR spectroscopy-based plant metabolomics in a 5-laboratory study,27 and a 
7-laboratory NMR environmental metabolomics study.28 Other studies have focused on GC-
MS plant metabolomics,29 NMR-based metabolomics for olive oil,30 and yeast metabolite 
profiling.31 Recently the Metabolomics Research Group of the Association of Biomolecular 
Resource Facilities (ABRF) conducted a “round-robin” study across 14 laboratories and 25 
different metabolomics platforms including GC-MS, LC-MS and NMR spectroscopy.32 In 
this study two groups of samples were generated by spiking 17 compounds at different levels 
into the NIST SRM 1950. The ABRF reported an 88.2% agreement in metabolite 
identification between platforms and a 33% quantitative agreement in terms of defining the 
fold-change in each metabolite between the two groups. Another study, the ‘metabo-ring’ 
initiative, also tested across several platforms (5 NMR and 11 LC-MS), using spiked 
samples and also real biological materials from a rodent study of vitamin D exposure. This 
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reported that, despite large differences in the number of spectral features produced and the 
heterogeneity of analytical conditions, the NMR spectral information between all platforms 
was very similar (average agreement of 64 to 91 %).33 The integration of semi-quantitative 
LC-MS lipidomic data generated in samples from three different large biobanks acquired in 
the time course of 3 years has been described.34 Moreover, in another study35 a high intra- 
and inter-laboratory reproducibility was reported of UHPLC-TOF-MS for urinary metabolic 
profiling. A total of 14 stable isotope labeled standard compounds were spiked into a pooled 
human urine sample, in dilution series and analytical features such as retention time drift, 
mass accuracy, signal intensity and adduct formation were evaluated. Recently, the inter-
laboratory robustness of the Biocrates® Bile Acids Kit in human and mouse plasma, 
involving 12 laboratories was reported36. Our study is currently unique in that we report full 
quantitative reproducibility of a widely-used targeted metabolomics platform, tested using 
both spiked QCs and a varied set of normal human plasma/serum.
The protocol used here consisted of a single sample processing procedure, however it 
requires two separate MS analytical runs, the LC-MS/MS and the FIA-MS/MS analysis of 
metabolites. LC offers the advantage of greater selectivity and lower susceptibility to matrix 
effects. However, for low intensity peaks (low concentration samples) visual inspection, 
optimisation of integration and manual integration may be necessary to get accurate results, 
as automatic peak integration software may select the incorrect integral. Ambiguous 
integration is also an issue for peaks with imperfect shapes e.g. split peaks or tailing peaks. 
One of the conclusions of our study is that a thorough visual inspection of the integration of 
the LC-MS/MS peaks is required for optimum precision. This suggests that specific 
guidance should be provided for targeted LC-MS protocols to support correct peak 
identification as was the case for Asn, Thr, Ac-Orn, trans- and cis-OH-Pro, carnosine and 
sarcosine in the manufacturer’s protocol used here.22 However, anecdotal evidence from the 
participating laboratories suggests that peak ambiguity was a problem for other metabolites 
for which guidance was not provided (Asp and Glu, and several biogenic amines) and that 
there was variability in how this was addressed at each centre. This may be reflected in the 
observation that 27/59 metabolites in the spiked QC samples showed an inaccuracy >30% in 
at least one sample for at least one laboratory. Unavoidably therefore, the overall quality of 
any targeted LC-MS metabolomics platform depends in part on the time spent on post-
acquisition review of the data and the experience and skills of the analysts in this regard.
Many of metabolites that were difficult to integrate reliably from LC-MS/MS (e.g. 
histamine, carnosine, DOPA, Dopamine, Nitro-Tyr, c4-OH-Pro and PEA) were also present 
at around or just below the limits of detection. In general for any assay, this will make 
analysis more prone to minor instrument and laboratory variations, errors with peak 
integration, data processing and fit to calibration curves. These metabolites are likely to be 
excluded from most studies of healthy individuals, although for some pathological 
conditions or different tissues, the levels of some could be elevated and become more readily 
detectable. A further source of variability is the definition of LOD itself. LODs can be 
calculated from repeated injection of a blank sample within each run (in our case phosphate-
buffered saline) or a historical value can be applied for a given instrument. In our study LOD 
was defined by the former approach, but this may lead to problems where the blank signal is 
improperly integrated, which could be the case for LC data. An alternative is to use repeated 
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injection of a blank sample for the FIA assay, while for LC data the analyst could make an 
informed decision based on in-house data. However, this is clearly also prone to inter-
laboratory variation and further work is required to resolve this issue.
While the integration of peaks is unambiguous for any FIA detection method, variation in 
background, selectivity and matrix effects do remain and are likely to be a major source of 
inter-laboratory variability. In our dataset it was necessary to normalise FIA-metabolite data 
in order to get acceptable inter-laboratory precision, particularly for sphingolipids. Our study 
indicates how normalisation to measurements made in each laboratory on a common 
standard reference material is a vital step making data comparable between laboratories 
where the output is considered largely ‘semi-quantitative’. While a single, commercially-
available reference material was used here (the NIST SRM 1950 plasma)24 using multiple 
QCs and reference materials could improve the robustness of this approach and 
comparability of data. Also QCs in 3 different levels are provided with the kit and we have 
demonstrated that using them for normalisation can improve the comparability of data 
obtained from different laboratories. Most metabolomics laboratories will use alternative 
pooled QC samples for assessing long-term platform stability. Exchange of these between 
metabolomics researchers and public dissemination of measurements made on these at 
multiple sites would make a significant impact on the inter-laboratory comparability of 
metabolomics data, benefitting the entire field.
Some important limitations to the simple normalisation approach we have used should be 
stated. Firstly it does not account for matrix effects between samples. A clear illustration of 
this was the effect of the high lipid sample, which significantly increased the inter-laboratory 
CV of several lipids. Secondly it does not take into account the underlying causes of error. 
For example corrections can be made for overlapping isotope peaks; while this is 
implemented in the protocol used, improvements can be continually made as the 
understanding of a metabolomics assay improves. It is interesting to note also that the FIA 
part of the present method uses a single point calibration curve while the LC part of the 
assay uses a seven point isotope dilution calibration curve for quantification. This is likely to 
have large influence on the susceptibility to matrix effects. Our study had several other 
general limitations. On average each sample was replicated 3-5 times; ideally more repeats 
would have minimized the impact of missing data. In our analyses we have focused on direct 
measurements and have not considered metabolite ratios, which are an important set of 
biomarkers for researchers using this platform.11
Conclusions
This is the first inter-laboratory assessment of a widely used targeted metabolomics platform 
for human serum and plasma, illustrating the reproducibility of the protocol and providing 
critical information for users to interpret such data appropriately. Data generated on a range 
of biological test materials using this targeted metabolomics kit are highly reproducible 
across multiple laboratories. Sets of metabolites likely to require manual integration review 
and/or likely to fall below limits of detection were identified, and these were the major 
sources of irreproducibility between laboratories. Normalisation to a reference material 
substantially improved the reproducibility of FIA-based, largely ‘semi-quantiative’ 
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measurements. We recommend the routine use of common, well-characterised reference 
materials within laboratories, such as the NIST 1950 SRM, and the public exchange of these 
data to facilitate comparability and integration of metabolomics datasets. High lipids affect 
the precision of the assay and further work should be carried out to assess the impact on 
studies of patients with dyslipidaemia or other conditions that could alter lipid levels. The 
specific instrumentation used, notably the use of UHPLC or HPLC, had a minor effect on 
comparability of data although we were limited to just two main MS platforms. Our work 
demonstrates that human metabolomics data generated in different laboratories using this 
platform can be directly combined with minimal pre-treatment facilitating large-scale 
integrated studies. Such meta-analyses of existing cohorts enhance the return on investment 
for often very laborious and costly biomarker studies, and will provide unprecedented power 
to detect novel associations between the human serum/plasma metabolome and disease, the 
exposome or genome in the years to come.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
An example of the effect of normalisation using the NIST SRM 1950 (TS-06), to the 
reported values of SM C24:0 by each laboratory, for our primary test set of 20 test materials.
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Figure 2. 
Distribution of inter-lab %CVs for the 20 test material and 189 metabolites (total 3780 inter-
lab %CV values), depicted per metabolite class, for the LC-assay and the FIA-assay. Data is 
shown for the non-normalised data, the data normalised to the mean or median values from 
SRM 1950 and data normalised to the mean or median values from QC level 2 provided with 
the kit.
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Figure 3. 
Distribution of the median inter-laboratory precision (%CV) of the 189 metabolites for six 
laboratories and 20 biological test materials, and also depicted per metabolite class.
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Figure 4. 
Accuracy comparison of the estimated concentrations measured by the AbsoluteIDQ™ p180 
Kit with the NIST reference values. The mean accuracy across all laboratories was used. 
Error bars represent the SD around the mean.
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Table 1
Median inter-laboratory %CV (prior and post normalisation), and total % BLD and % missing values, for the 
20 test material and 189 metabolites. The column indicating missing includes the total of not acquired data 
‘NQ’, ‘NA’ values, zero values and outliers.
Metabolite
class
Median InterLab
%CV [90%CI]
Non-Normalised
Median InterLab
%CV [90%CI]
Normalised
% total
(BLD+missing)
Amino Acids 7.1 [4.5-13] - 1.3
Biogenic Amines 27 [6.6-100] - 43.4
Carnitines 34 [11-61] 12 [7.2-18] 48.0
Di-acyl PC
(PC aa) 17 [11-36] 6.4 [4.8-12] 6.7
Alkyl-acyl PC
(PC ae) 15 [10-29] 5.9 [4.8-11] 4.0
Lyso PC 18 [12-66] 8.1 [6.5-28] 10.4
Sphingolipids 68 [37-120] 6.7 [5.1-14] 5.3
Sum of hexoses 9.3 [7.5-16] 6.3 [3.9-13] 0.8
Total 18 [8.2-61] 7.6 [5-27] 18.7
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